Novocure.com
KEYNOTE B36 – Lung Cancer Clinical Trial overview The KEYNOTE B36 study is intended for patients who have been diagnosed with, but have not been treated for, PD-L1 positive advanced or metastatic non-small cell lung cancer (NSCLC). This clinical study is evaluating the safety and efficacy of Tumor Treating Fields (TTFields) delivered by the NovoTTF-200T device concomitant […]
EF-33
EF-33 – Recurrent Glioblastoma Clinical Trial overview EF-33 The EF-33 trial is intended for patients who have recently been diagnosed with recurrent Glioblastoma Multiforme (GBM). Optune® has been approved for the treatment of recurrent and newly diagnosed GBM by the Food and Drug Administration (FDA) in the United States under the Premarket Authorization (PMA) pathway […]
PANOVA-3
PANOVA-3 – Pancreatic Cancer Clinical Trial overview The PANOVA-3 study is a pivotal, randomized, open-label study of Tumor Treating Fields (TTFields, 150kHz) concomitant with gemcitabine and nab-paclitaxel for front-line treatment of locally-advanced pancreatic adenocarcinoma. This study has completed its enrollment. Please go to find a trial to search other options in your area, or contact us. The PANOVA-3 […]
ZL-8301-001
Zl-8301-001 – Gastric Cancer Clinical Trial overview ZL-8301-001 Gastric Study The ZL-8301-001 Gastric study is intended for patients who have recently been diagnosed with unresectable gastroesophageal junction (GEJ) adenocarcinoma or gastric (GC) adenocarcinoma. This clinical study is evaluating the safety and efficacy of Tumor Treating Fields (TTFields) delivered by the NovoTTF-200T device when added to […]
TRIDENT
TRIDENT – Glioblastoma Clinical Trial overview The TRIDENT study is for patients recently diagnosed with glioblastoma (GBM). This clinical trial is evaluating the safety and efficacy of Tumor Treating Fields (TTFields) delivered by the Optune® treatment paired with radiation therapy and temozolomide in newly diagnosed GBM patients [About TTFields]. All patients participating in this study […]
ENGOT-ov50 / INNOVATE-3
ENGOT-0V50/INNOVATE-3 – Ovarian Cancer Clinical Trial overview The ENGOT-ov50/INNOVATE-3 study is a pivotal (like a Phase 3), randomized, open label study. This clinical study is evaluating the safety and efficacy of Tumor Treating Fields (TTFields), delivered by the NovoTTF-200(O) device concomitant with a standard chemotherapy agent paclitaxel, for patients recently diagnosed with recurrent ovarian cancer. This […]
LUNAR
LUNAR – Non-small Cell Lung Cancer Clinical Trial overview The LUNAR study is a pivotal, randomized, open-label study of Tumor Treating Fields (TTFields) concurrent with standard of care therapies for treatment of stage 4 non-small cell lung cancer (NSCLC) following platinum failure. Update: The LUNAR study met its primary endpoint, demonstrating a statistically significant and […]
METIS
METIS – Brain Cancer Clinical Trial overview EF-25 / METIS: A pivotal (analogous to drug Phase III), randomized, controlled study, designed to evaluate the efficacy and safety of Tumor Treating Fields (TTFields), generated by a medical device, NovoTTF-200M in patients with 1-10 newly diagnosed brain metastases from non-small cell lung cancer (NSCLC). This study has […]